{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for azelaic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Investigational
Source:
INN:golocdacimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04087018: Phase 1 Interventional Completed Advanced Solid Tumors
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02877134: Phase 2 Interventional Completed Crohn Disease
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01678417: Phase 2 Interventional Unknown status Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:briquilimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efocipegtrutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pivekimab sunirine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04669899: Phase 1/Phase 2 Interventional Completed Cancer
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:manfidokimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03700294: Phase 1 Interventional Terminated Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
